The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer
Implications for using the Oncotype DX Breast Recurrence Score to help tailor therapy for patients with HR-positive, HER2-negative breast cancer based on data demonstrated in the TAILORx and RxPONDER studies.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
March 13th 2022Article
In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.
